patient recruitment and Rob Grant for statistical advice. We also thank Monash University, Melbourne, Australia, for access to their FODMAP food composition database for analysis of FODMAP intake. has been reported to reduce symptoms in some patients with irritable bowel syndrome (IBS). We performed a randomized, placebo-controlled study to determine its effects on symptoms and the fecal microbiota in patients with IBS.
Abbreviations

Methods:
We performed a 2x2 factorial trial of 104 patients with IBS (18- Results: There was no significant interaction between the interventions in adequate relief of symptoms (P=.52) or Bifidobacterium species (P=.68). In the intention-to-treat analysis, a higher proportion of patients in the low FODMAP diet had adequate symptom relief (57%) vs than in the sham diet group (38%), although the difference was not statistically significant (P=.051). In the per-protocol analysis, a significantly higher proportion of patients on the low FODMAP diet had adequate symptom relief (61%) than in the sham diet group (39%) (P=.043). Total mean IBS-Severity Scoring System score was significantly lower for patients on the low FODMAP diet (173±95) than the sham diet (224 ± 89)(P=.001), but not different between those given probiotic (207 ± 98) or placebo (192 ± 93)(P=.721) Abundance of Bifidobacterium species was lower in fecal samples from patients on the low FODMAP diet (8.8 rRNA genes/g) than patients on the sham diet (9.2 rRNA genes/g) (P=.008), but higher in patients given probiotic (9.1 rRNA genes/g) than patients given placebo (8.8 rRNA genes/g) (P=.019). There was no effect of the low FODMAP diet on microbiota diversity in fecal samples. dysregulation, the GI microbiota, altered regulation of the gut-brain axis, and psychosocial factors. 4 An incomplete understanding of the pathophysiology of IBS and its phenotypic heterogeneity has led to symptom-directed treatment approaches including antispasmodics and anti-diarrheals. However, less than 40% of patients are satisfied with their current treatments. 5 Most patients with IBS believe their symptoms are diet-related. Dietary restriction of fermentable carbohydrates (low FODMAP diet) is now widely used in the management of IBS. These carbohydrates increase small intestinal water and colonic gas. 6 Their dietary restriction has been investigated in a number of trials with up to 70% of patients reporting symptomatic benefit. 6 Only one placebo-controlled trial of the low FODMAP diet has been undertaken in IBS, however this was a feeding study in which all dietary intake was provided to participants. 7 Trials of dietary advice replicate how dietary manipulation is undertaken in practice and therefore better reflect effectiveness in the clinical setting. Placebo-controlled trials are especially important in IBS where the placebo response is known to be considerable. 8 A placebo-controlled dietary advice trial of the low FODMAP diet has yet to be performed, in part due to the difficulty of designing a blinded placebo diet that modifies dietary intake without altering intakes of nutrients or fermentable carbohydrates.
Conclusions
The low FODMAP diet has been shown to induce alterations in some genera of the GI microbiota, including bifidobacteria 9,10 and Faecalibacterium prausnitzii. 9 Reductions in bifidobacteria are particularly relevant to IBS symptomatology given their inverse association with abdominal pain. 11 There is also evidence of reduced microbiome diversity in IBS 12 , as well as in other disorders (e.g. inflammatory bowel disease, obesity and diabetes). 13, 14 There is reason to suspect that the low FODMAP diet may impact global microbial community structure, however the effect has never been compared with placebo. 15 It also remains to be demonstrated whether any potential clinical benefit of the low FODMAP diet in IBS is offset by impacts on specific microbiota (e.g. bifidobacteria) or on community structure, known to be a key factor influencing gut health and systemic physiology.
Therefore, approaches that prevent the microbiota-modifying effect of the low FODMAP diet are required. Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit on the host, and some probiotic species are effective in the management of IBS. 16 However, no trials have investigated whether probiotics can modify the effect of the low FODMAP diet on the microbiota.
We designed a placebo-controlled trial to address these important questions. Firstly, we aimed to investigate the effect of the low FODMAP diet compared with a placebo (sham) diet, and secondly, to investigate whether the low FODMAP diet-induced alterations in the microbiota could be prevented through concomitant probiotic therapy compared with placebo.
Methods
Study design and participants
We performed a 2x2 factorial design, multicentre, randomised, placebo-controlled trial from 
Randomisation and masking
A computerised random allocation sequence was prepared by a researcher not involved in screening or recruitment. Patients were randomised in a 1:1 ratio to both diet (sham vs low The diet allocation was concealed in an opaque envelope that was only opened after all baseline data had been collected.
Patients were masked to both diet and supplement allocations. The two diets were described to patients as both altering carbohydrate intake, but one designed as a placebo diet and the other being the true diet under investigation. The researcher who conducted the trial visits, a registered dietitian, provided the dietary advice and was not able to be masked to diet allocation but was masked to supplement allocation. The placebo and probiotic supplements were identical in appearance, taste and presentation. Labelling of supplements was performed by researchers not involved in patient screening or recruitment such that boxes of supplement sachets were identifiable only by participant randomisation numbers. Allocation to diet and supplement was masked throughout data collection, laboratory analysis, data input and data analysis.
Procedures
The low FODMAP diet involves restricting dietary intake of fructans, galactooligosaccharides (GOS), lactose, fructose in excess of glucose, and polyols, and is described elsewhere. 17 Blinding dietary advice trials is notoriously challenging and therefore the sham diet was designed bespoke for this trial to fulfil the following criteria: 18 in other recent scientific publications) and was provided in sachets in freeze dried form with maltose and silicon dioxide as inactive excipients. The placebo sachets were prepared by the same manufacturer as the probiotic product. The placebo sachets contained the same inactive excipients but no bacteria. Participants received two sachets per day (11.95 log10 bacteria in the intervention group) to be taken in the morning with cold food or fluid.
Patients were considered compliant to the supplement if 80% of sachets were taken based on return of all unused sachets. A greater threshold for compliance was used for the probiotic/placebo, in line with those used in other probiotics trials and because compliance once per day is easier than extensive dietary modification at every meal, snack and drink.
Assessments
The incidence and severity of 15 gastrointestinal symptoms and overall symptoms were measured daily for seven days prior to baseline using the Gastrointestinal Symptom Rating Scale (GSRS), 20 and stool frequency and consistency was recorded using the Bristol Stool Form Scale. A 7-day food diary was used to measure dietary intake and FODMAP intake was quantified using dietary analysis software containing the most comprehensively analysed FODMAP food composition database available. [21] [22] [23] At the baseline visit, global and individual symptoms were also measured using the IBS Symptom Scoring System (IBS-SSS). 24 Generic and disease-specific HRQOL were measured using the SF-36 25 and IBS-QOL 26 , respectively. Then, after all data had been collected, patients were randomised to dietary advice (sham, low FODMAP diet) and supplement (placebo, probiotic). Patients were telephoned weekly for assessment of dietary compliance, to address dietary questions and to ensure IBS medication remained stable. All outcomes were then repeated at four weeks (follow-up) as well as 'adequate symptom relief' (did you have adequate relief of your symptoms over the past seven days). 27 A whole fresh stool sample was collected within one hour of passage and stored immediately on ice at baseline and follow-up. It was homogenized in a stomacher for four minutes and multiple aliquots were taken and stored at -80°C until analysis. Quantitative polymerase chain reaction (qPCR) was performed to quantify abundance of Bifidobacterium species. 16S rRNA sequencing was performed to evaluate α-diversity (number of operational taxonomic units [OTU] i.e. number of species, or richness) and β-diversity (differences in species composition between baseline and follow-up) and to confirm the abundance of Bifidobacterium species from qPCR analysis (supplementary Information).
Outcomes
As the outcomes of interest were the impact of diet and supplement on symptoms and microbiota, the co-primary outcomes were IBS symptoms ('adequate symptom relief') and
stool Bifidobacterium species concentration at follow-up, measured using qPCR. Prespecified secondary outcomes were individual GI symptoms (IBS-SSS and GSRS), stool output, HRQOL, microbiota diversity and nutrient intake. Adverse events were recorded at weekly telephone calls and at the follow-up visit.
Statistical analysis
The sample size calculation was based on the co-primary endpoints assuming no interaction between the two interventions. For the first co-primary outcome (symptoms), the estimated response to low FODMAP diet advice was based upon 'adequate symptom relief' from the only randomised controlled trial (RCT) available at the time (68%) 10 and the estimated response to sham advice was based on the response rate of controls in a meta-analysis of IBS trials and two previous trials of the low FODMAP diet (36%). 10, 28, 29 The estimated response to the probiotic and placebo was based upon the combined global response data from previous studies of the probiotic supplement. 30, 31 Based on logistic regression and assuming a power of 80% and a 2-sided significance level of 5%, the main effects of diet (sham vs low FODMAP diet) could be estimated with 88 patients. Based on previous research from our centre 10 , attrition of at least 12% was anticipated, leading to an overall sample size of at least 100 such that the per protocol analysis would be adequately powered. For the second co-primary outcome (Bifidobacterium), the expected abundance of stool Bifidobacterium species in response to the low FODMAP diet was taken from the only RCT at that time 10 and the expected abundance in response to probiotic was taken from a RCT of the same product. 32 The sham and placebo groups were expected to have no impact on abundance of Bifidobacterium species and therefore values from control groups were used. Based on linear regression, assumed power of 80% and overall 2-sided significance of 5%, the main effects for the Bifidobacterium outcome could be estimated with 28 patients, which ensured the trial was powered for both clinical and microbiological outcomes. All authors had access to the trial data and reviewed and approved the final manuscript.
Results
Patients were recruited between 28 January 2013 and 21 Table 3 ).
Although there were no differences between groups in total score for SF-36 and IBS-QOL (Table 4 ), there were higher scores for role limitations due to physical health (p=0.033) and energy/fatigue (p=0.016) for SF-36 and higher scores for body image (p=0.001), social reaction (p=0.026) and relationships (p=0.041) of IBS-QOL in patients on the low FODMAP diet compared with sham diet, indicating better quality of life in these domains. There was no effect of probiotic on HRQOL compared with placebo (Table 4) .
Microbiota endpoints
Regarding the microbiota co-primary endpoint using the qPCR analysis, at follow-up there was a lower absolute Bifidobacterium species abundance following the low FODMAP diet (95% CI for differences in change 0.63% to 1.90%, p=0.00017, Figure 2B ). There was no difference in relative abundance of Streptococcus species for the low FODMAP diet compared with sham diet (p=0.1141, Figure 2B ). There were also no differences in change in relative abundance of Lactobacillus species between baseline and follow-up between the low FODMAP diet and sham diet (p=0.5782) or between the probiotic and placebo group (p= 0.9521, Figure 2C ).
There were significant differences in absolute abundance of Bifidobacterium species measured using qPCR between the four randomised groups at follow-up, i.e. sham diet/placebo (8.9 rRNA genes/g, SD Whether the positive impact on some domains of HRQOL translates into reduced healthcare utilisation or has wider economic implications requires evaluation.
'Adequate symptom relief' was reported in more patients receiving probiotic than the placebo. Although this was statistically significant this may represent a type I error; the trial was not powered to detect differences in this outcome for the probiotic and yet the effect size was much higher (57%) compared with previous studies (33%-46%) 30, 31 , and no differences were found in the per protocol analysis. Furthermore, the 'adequate symptom relief' outcome distinctly deviates from other clinical endpoints in this trial.
As hypothesised, the low FODMAP diet led to a reduction in stool Bifidobacterium species according to qPCR and 16S rRNA sequencing. These findings are likely the result of restriction of prebiotic carbohydrates, essentially leading to the opposite effect to that which occurs during prebiotic supplementation (an 'anti-prebiotic' effect). Bifidobacteria have established immunomodulatory effects and have been inversely associated with clinical symptoms in IBS. 11 The impact of the reduction of Bifidobacterium species by the low FODMAP diet on clinical symptoms in IBS, or on colonic function is unknown. However, the probiotic, which contained bifidobacteria strains, resulted in a greater abundance of Bifodobacterium species according to qPCR analysis. This finding was not replicated in the sequencing analysis, although this discrepancy is not uncommon and can be attributed to the fact that qPCR is a quantitative method using specific primer sets to enumerate the population of interest whereas 16S rRNA sequencing targets the whole bacterial community, sometimes failing to provide extensive coverage for specific genera. Given the lack of interaction between diet and probiotic interventions in this study, the effects of each can be considered additive. We have therefore shown that the low FODMAP diet-induced reduction in Bifidobacterium can be modified with the addition of a specific bifidobacteriacontaining probiotic.
Reduced microbiome species richness is evident in IBS, as well as in inflammatory bowel disease, obesity and diabetes. 13, 14 Two previous studies report no within-group change in microbiota diversity in response to the low FODMAP diet, 15, 35 This RCT evaluated the therapeutic benefit of low FODMAP dietary advice, as utilised in clinical practice, above the effect of placebo, which is known to have a powerful effect in IBS. 8 In dietary intervention trials, the problem of designing a control group is often resolved through feeding studies that deviate considerably from clinical practice. Therefore an important strength of the current study is the implementation of a placebo sham diet that required equivalent dietary counselling, disruption to daily life, and which changed dietary intake but not FODMAP intake.
Limitations of this RCT include the difficulty of maintaining blinding. Blinding is challenging in dietary intervention trials compared with nutrient or drug trials. However, the best attempts were made to blind patients to their allocated diet through a range of approaches:
the sham diet also focused on modifying intake of carbohydrate-rich foods, required modification of a similar number of foods and specialist foods compared with the low Fourth, there is the problem of collinearity, which is unavoidable in dietary exclusion studies (i.e. changing one component of the diet leads to compensatory changes in other components). Although macronutrient and fibre intake was maintained in this study, there may have been changes in unmeasured dietary substrates (e.g. polyphenols, gluten) that could contribute to the observed findings. This limitation is also applicable to the sham group; there may have been alteration in unmeasured dietary components that impacted the findings. However, we carefully measured intake of numerous dietary constituents with an established potential to impact IBS symptoms (e.g. fiber, fat) and these did not change,
suggesting it fulfilled its purpose as a sham diet. Fifth, changing dietary intake may impact on other physiological parameters (e.g. transit time) that might independently affect microbiota composition. Finally, this study raises questions regarding the use of a dichotomous endpoint as a primary outcome measure given the disparity between this outcome and the various non-dichotomous endpoints used (e.g. IBS-SSS, GSRS). Trials in IBS-C have also reported clinically important changes in individual symptoms in patients that did not meet a dichotomous endpoint. 36 Further research should prospectively evaluate longer term durability of the low FODMAP diet, which has been associated with symptom benefit in retrospective studies. 19, 38 It should also address the low FODMAP diet-induced microbiota disruption to determine whether the microbiota changes persist over time, and whether co-administration of probiotic should be considered in the long term. Cost-benefit analysis of both interventions will confirm their utility for long term use. Furthermore, whether the mucosal microbiota compartment is affected, whether changes in microbiome function occur (dependent or independent of the compositional shift) and whether this leads to short-term or long-term consequences require evaluation. Furthermore, the identification of biomarkers that predict response to the low FODMAP diet would be extremely valuable. IBS is a heterogeneous syndrome with inter-individual differences in the contribution of physiological, cognitive and behavioral components to the manifestation of symptoms. It is currently unclear to what extent each of these will respond to dietary and probiotic intervention.
In conclusion, we have demonstrated that low FODMAP dietary advice leads to improvement in overall and specific GI symptoms in IBS. In fact, 73% of patients reported a global clinical response based on the IBS-SSS, and 57% report response based on the dichotomous primary outcome, although the limitations of the latter endpoint are acknowledged. At a conservative estimate, this corresponds to a 2-3 greater odds of response to low FODMAP dietary advice compared with placebo dietary advice, which is equivalent to several pharmaceutical treatments (e.g. antispasmodics, antidepressants). 37 We also present findings related to the impact of the low FODMAP diet on the microbiota, and the first evidence that the effect of the low FODMAP diet on bifidobacteria can be modified by adjunctive probiotic therapy. 
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